Encore Medical Research-Weston
Weston, Florida 33331
1 studies enrolling now · 13 studies all time
What they study most
Atopic Dermatitis, Bipolar Disorder, COVID-19, Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Distal Sensory Polyneuropathy, Neuropathic Pain, Obesity, Overweight, Overweight or Obesity, Rheumatoid Arthritis
Studies at this site
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) — Recruiting now
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) — Running, not enrolling
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — Running, not enrolling
- Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy — Completed
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight — Running, not enrolling
- An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis — Completed
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
- Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis — Completed
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections — Completed
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
- A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness — Completed